CPT code 40819: Labial and buccal frenectomy billing guide
CPT code 40819 covers lip and cheek frenectomies CPT code 40819 is the procedure...
Last Updated: Oct 8, 2026
CCSD code AA489 is the private health insurance billing code for transtympanic chemical labyrinthectomy. In this outpatient procedure, an ototoxic drug is injected through the eardrum to permanently switch off balance function in a diseased inner ear. ENT practices in the UK and Ireland submit it to private medical insurers such as Bupa, AXA Health, Aviva and VitalityHealth.
The procedure is reserved for refractory unilateral Meniere’s disease and can cost the patient hearing in the treated ear. That is why insurers almost always expect pre-authorization and a full documentation trail before they pay an AA489 claim.
Key takeaways
CCSD code AA489 covers transtympanic chemical labyrinthectomy, not surgical labyrinthectomy (D2630 or D2620) or a transtympanic steroid injection (D2070).
The code applies only to private health insurance billing in the UK and Ireland. NHS-funded care is coded and paid through separate systems.
Gentamicin is the agent most commonly used, but the code is not drug-specific, provided the intent is vestibular ablation.
Most major insurers expect pre-authorization before the procedure is performed, and a missing authorization number is the leading cause of claim rejection.
Found our content helpful?
CCSD code AA489: Definition and code system context
CCSD code AA489 describes transtympanic chemical labyrinthectomy in the schedule maintained by the Clinical Coding & Schedule Development (CCSD) Group. The schedule is the standard procedure reference for claims to UK and Ireland private medical insurers (PMIs). NHS-funded care is coded and paid through separate systems, so an AA489 claim sent through NHS channels will be rejected.
AA489 sits in chapter 5.3.0 Inner Ear, under 5.0.0 Ear, Nose & Throat, with the reference Fe.045. Its official descriptor names both the method and the route. The approach is chemical rather than surgical, and the drug reaches the inner ear through the eardrum.
Don’t choose a code by its number. The neighboring AA4xx codes, such as AA460 and AA461, are trigeminal nerve procedures. The ear codes closest to AA489 are D2070, D2610, D2620 and D2630, and you can compare their descriptors in our CCSD code library.
What the code covers: Procedure overview
Transtympanic chemical labyrinthectomy involves injecting an ototoxic agent through the tympanic membrane (eardrum) into the middle ear space. The drug diffuses through the round window membrane into the inner ear. There it destroys vestibular hair cells in the membranous labyrinth, permanently ablating balance function in that ear and removing the source of episodic vertigo.
The procedure takes place in an outpatient setting, not under general anesthesia. The consultant ENT surgeon or neurotologist positions the patient with the treated ear uppermost. They numb the eardrum with a local anesthetic, or use an existing myringotomy, and inject the agent into the middle ear. The patient then holds that position for 20 to 30 minutes so the drug can absorb.
Multiple sessions may be required, depending on the protocol in use:
- Titration protocol: Repeated low-dose injections, with vestibular assessment between sessions, until sufficient ablation is confirmed.
- Fixed-dose protocol: A set number of injections (commonly three to five) delivered at defined intervals.
Where multiple sessions are needed, each injection episode may need its own claim. Check the CCSD technical guidance on whether repeat injections within one clinical episode go under a single AA489 claim or are coded individually.
Clinical indications: When is AA489 used?
CCSD code AA489 is used mainly for unilateral Meniere’s disease (endolymphatic hydrops) that has not responded to conservative medical management. Insurers expect documented failure of dietary measures, betahistine and diuretics before they authorize AA489.
The key clinical criteria for appropriate use of AA489 are:
- Confirmed unilateral Meniere’s disease with audiometric evidence.
- Disabling episodic vertigo that has not responded to at least three to six months of medical management.
- Substantially reduced or absent useful hearing in the affected ear, since the procedure risks further sensorineural hearing loss (SNHL).
- A patient counseled on the permanent nature of vestibular ablation and the hearing risk.
Using AA489 for bilateral Meniere’s disease, or while the affected ear still has useful hearing, will trigger insurer scrutiny. The procedure may also treat other refractory unilateral vestibular disorders, but Meniere’s disease is the primary indication on most AA489 claims.
How the procedure is performed: Step-by-step for coders
Knowing the procedural steps helps billing staff check that the procedure note contains what insurers expect. The typical sequence for intratympanic gentamicin treatment is:
- Patient positioning: The patient lies supine with the affected ear uppermost.
- Local anesthesia: EMLA cream or phenol is applied to the tympanic membrane to reduce discomfort, unless a myringotomy is already present.
- Injection: The consultant uses a fine needle to inject gentamicin (or another ototoxic agent) into the middle ear space through or around the tympanic membrane.
- Post-injection hold: The patient stays still for 20 to 30 minutes, avoiding swallowing where possible, to maximize drug contact with the round window.
- Follow-up: Audiological and vestibular function tests are scheduled to assess the response. If further ablation is needed, a repeat session is arranged.
Drug concentration, volume and the number of injections vary by surgeon protocol. Coders should never infer a dose for the claim. Record whatever appears in the procedure note, and confirm documentation exists for each billed episode.
AA489 vs. related CCSD codes: Choosing the right code
The most common coding error with AA489 is selecting a related code that describes a similar but distinct procedure. The table below compares AA489 with the codes most likely to be confused with it.
The critical distinction between AA489 and D2070 is the drug class and intent. Gentamicin is ototoxic and destroys vestibular function, while a transtympanic steroid injection reduces inflammation to rescue hearing in sudden sensorineural hearing loss. Submitting D2070 instead of AA489, or vice versa, is a material error that triggers a clinical query and likely a denial.
Endolymphatic sac surgery is a separate route for refractory Meniere’s disease, billed under D2610 as an operating-room procedure. It aims to relieve pressure rather than ablate balance function.
Surgical vs. chemical labyrinthectomy: Coding implications
Surgical labyrinthectomy (D2630, or D2620 for the membranous variant) and chemical labyrinthectomy (AA489) share one goal, permanent vestibular ablation. They reach it by completely different means. Coders must not use the terms interchangeably.
- D2630 or D2620 (surgical): Performed under general anesthesia in an operating room, where the labyrinthine structures are physically removed. It needs a full operative record and an anesthesia record, and facility costs are billed separately.
- AA489 (chemical): Performed with the patient awake in a treatment room under topical anesthesia. There are no operating-room costs, and the record is a procedure note rather than a surgical report.
The practical signal for coders is the setting. If the patient went to the operating room under general anesthesia, AA489 is wrong and the claim belongs under D2630 or D2620. If the patient was awake in a consulting or treatment room, a surgical code is wrong. The decision path below combines the setting test with the drug test.
Documentation requirements for AA489 claims
A valid AA489 claim needs documentation that establishes both the clinical justification and the procedural detail. Structured digital forms filled in at the point of care make it harder to miss an element at billing time. Insurers consistently query or deny claims that lack any of the following:
- Confirmed Meniere’s diagnosis: A consultant or referral letter stating the diagnosis, supported by audiometry showing unilateral sensorineural hearing loss at low and mid frequencies.
- Evidence of conservative treatment failure: A record of at least three to six months of medical management (betahistine, diuretics, dietary modification) with documented symptom persistence.
- Pre-authorization reference number: Obtained before the procedure from the insurer’s provider portal. Without it, most insurers will not pay regardless of clinical merit.
- Procedure note: The agent used (e.g. gentamicin), the concentration and volume injected, and the injection site (tympanic membrane or via myringotomy). It also records the patient position and the post-injection hold time.
- Post-procedure outcome note: Vestibular function assessment and audiogram results at follow-up, confirming ablation and documenting any change in hearing thresholds.
The Royal College of Surgeons of England’s standards require procedural records to be legible, dated and signed. They must also hold enough detail for another clinician to understand what was done. Billing staff should flag incomplete procedure notes before the claim is submitted, not after a rejection.
Pre-authorization: What private insurers require for AA489
Most major UK private medical insurers require pre-authorization before AA489 can be performed and claimed. Requirements vary by insurer and change each year, so check each insurer’s current provider portal rather than last year’s guidance. The general pattern across Bupa, AXA Health, Aviva and Cigna is as follows:
- Bupa: Pre-authorization goes through the Bupa provider code portal. Clinical criteria include a confirmed Meniere’s diagnosis and documented failure of the treatment pathway.
- AXA Health: Authorization goes through the AXA Health provider hub, which expects a completed specialist referral and audiometry evidence with the request.
- Aviva: Review the Aviva fee schedule for the current reimbursement amount and pre-authorization pathway. Clinical evidence is required upfront.
- Cigna and VitalityHealth: Pre-authorization goes through their own provider portals. Coverage varies by individual policy, so verify member eligibility at the point of referral.
Timing matters. Pre-authorization requests submitted after the procedure cannot be backdated, and retrospective authorization is rarely granted for elective vestibular procedures. Start the request as soon as the consultant decides to proceed with AA489.
Pro Tip
Build a pre-authorization checklist into your AA489 booking workflow. It should confirm the Meniere’s diagnosis, attached audiometry, documented conservative treatment, the portal submission and the authorization number on the appointment. Catching a missing element before the procedure prevents the most common AA489 denial.
Common reasons AA489 claims are denied
Denials for CCSD code AA489 cluster around five recurring problems. Addressing each one at the point of claim submission reduces rework and speeds up payment.
- Missing pre-authorization: The single most common denial. If the authorization number is absent from the claim, most insurers will reject it without clinical review.
- Wrong code selected: D2070 (transtympanic steroid injection) submitted when AA489 (chemical labyrinthectomy) was performed, or vice versa. The drug class and clinical intent must match the code.
- Insufficient Meniere’s documentation: A diagnosis in a referral letter without supporting audiometry, or no record of failed conservative treatment, lets the insurer query clinical necessity.
- Bilateral billing under a single code: AA489 applies to one ear per episode. A bilateral procedure (unusual, and clinically controversial) needs a separate claim line with a side modifier for each ear. Submitting both ears under one AA489 code will trigger a query.
- Policy exclusion: Some individual PMI policies exclude vestibular conditions or limit the number of covered intratympanic procedures. Checking the member’s policy schedule before booking prevents a policy-level denial on a fully documented, authorized claim.
Codes commonly billed alongside CCSD code AA489
AA489 rarely appears on its own. The following services may legitimately appear on the same claim, or on related claims within the same episode of care. For Bupa-recognized codes and fee categories, see our guide to Bupa CCSD codes.
Insurer unbundling rules vary. Some insurers will not pay separately for audiometry performed on the same day as AA489 if they consider it integral to the procedure. Check the insurer’s fee schedule and unbundling guidance before listing ancillary codes on the same invoice.
What CCSD code AA489 does not cover
Standard code references rarely list exclusions, but coders need them to avoid incorrect submissions.
- Transtympanic steroid injections: Corticosteroid injections into the middle ear treat sudden sensorineural hearing loss or autoimmune inner ear disease. They are coded under D2070, not AA489. The drug class is the deciding factor.
- Surgical labyrinthectomy: Physical removal of labyrinthine structures in the operating room is D2630 (osseous) or D2620 (membranous). Labeling an operating-room case as AA489 is both clinically inaccurate and fraudulent.
- Endolymphatic sac decompression or shunting: D2610 covers operations on the endolymphatic sac, which are distinct from transtympanic chemical ablation.
- Canal-based vestibular procedures: Procedures targeting the semicircular canals (e.g. posterior canal plugging for BPPV) have separate codes and are not captured under AA489.
- Contralateral ear on the same claim: AA489 is unilateral by definition. Billing the other ear under the same code without a separate claim line and clinical justification will be rejected.
- NHS procedures: CCSD codes do not apply to NHS-funded care, which is coded and paid through separate NHS systems.
Pro Tip
When a patient has bilateral Meniere’s disease, the treating consultant may schedule AA489 for each ear separately, weeks or months apart. Code each session independently against the correct ear, with a fresh pre-authorization request for the second side. Never assume that authorization for one side covers the other ear.
How Pabau keeps AA489 claims and ENT documentation audit-ready
In many private ENT practices, the authorization number sits in an insurer portal and the procedure note sits in a consultant letter. Someone then rebuilds the claim from both by hand. A missing hold time or reference number usually surfaces only when the insurer sends a query.
Pabau, the practice management platform we build, keeps the referral, audiometry, consent and procedure note on one patient record. Procedure note templates make the agent, volume and hold time required fields. Its private practice claims software then raises the insurer invoice for AA489 from that same record.
The result is a claim that leaves with the authorization number and the supporting notes already attached. Your billing team spends less time answering queries and more time on claims that are ready to pay.
Manage AA489 claims and ENT documentation in one place
Pabau helps private ENT practices structure procedure notes, record pre-authorization details, and keep billing records audit-ready. See how it works.
Conclusion
An AA489 claim is won or lost before the patient reaches the treatment room. Get the authorization number, the audiometry and the record of failed conservative treatment on file first. Then the claim carries what every insurer checks.
The trade-off worth remembering is speed against certainty. Booking the injection before the insurer replies may save a week, but retrospective authorization is rarely granted for elective vestibular procedures.
Book a demo to see how Pabau keeps authorization numbers, procedure notes and claims together for private ENT practices.
Continue your research
Need a reference for Bupa’s recognized CCSD codes and fee schedules? Pabau’s Bupa CCSD guide covers procedure codes, insurer-specific fee categories and submission guidance for UK private practice.
Billing a surgical labyrinthectomy instead? CCSD code D2630: Osseous labyrinthectomy explains the operating-room alternative to AA489 and what its claim needs.
Is the consultant planning endolymphatic sac surgery? CCSD code D2610: Endolymphatic sac operation walks through the code for pressure-relief surgery in Meniere’s disease.
Looking up another ENT or inner ear procedure? The CCSD code library lists every CCSD procedure guide we publish for UK and Ireland private billing.
Frequently asked questions
What does CCSD code AA489 cover?
CCSD code AA489 is the billing code for transtympanic chemical labyrinthectomy. In this outpatient procedure, an ototoxic agent (typically gentamicin) is injected through the eardrum to ablate vestibular function. It covers the procedure only, so consultations, audiometry and vestibular function tests are coded separately.
How does AA489 differ from a transtympanic steroid injection?
AA489 uses an ototoxic agent to permanently destroy vestibular hair cells. A transtympanic steroid injection, coded D2070, uses corticosteroids to reduce inflammation and typically aims to rescue hearing after sudden sensorineural hearing loss. The drug class and clinical intent decide the code, so submitting D2070 when gentamicin was used is a coding error.
What drug is used in chemical labyrinthectomy?
Gentamicin is the agent most commonly used in transtympanic chemical labyrinthectomy because of its selective vestibulotoxic effect. CCSD code AA489 is not drug-specific, provided the agent is ototoxic and the intent is vestibular ablation. Coders should record whichever agent the consultant names in the procedure note rather than assume gentamicin.
Does AA489 require pre-authorization from private health insurers?
Yes, in most cases. Bupa, AXA Health, Aviva and Cigna typically require pre-authorization before AA489 is performed. Requirements and portals differ by insurer and change each year, so check each insurer’s current provider portal rather than prior-year guidance.
How is surgical labyrinthectomy coded differently from chemical labyrinthectomy?
Surgical labyrinthectomy is coded D2630 (osseous) or D2620 (membranous) and is performed under general anesthesia in an operating room. Chemical labyrinthectomy (AA489) is an outpatient injection performed with the patient awake under topical anesthesia. The setting, anesthesia, record type and facility costs all differ, so the wrong code on either procedure is a material billing error.
Is chemical labyrinthectomy covered by Bupa, AXA and Aviva?
Coverage depends on the individual policy rather than the insurer alone. Bupa, AXA Health and Aviva all recognize CCSD code AA489, but individual policies may exclude vestibular conditions or cap covered intratympanic procedures. Verify member eligibility and the policy schedule before booking to avoid a policy-level denial on a correctly coded claim.
Found our content helpful?
